Colorectal Cancer Clinical Trial
Official title:
Omega-3 Fatty Acids and Postoperative Complication After Colorectal Surgery
To discover whether an Omega-3 fatty acid (eicosapentaenoic acid/EPA and docosahexaensyre/DHA) enriched nutritional supplement given 7 days preoperatively and 7 days postoperatively may reduce the frequency of postoperative infectious complications defined as: pneumonia, wound infection, urinary tract infection, peritonitis (including anastomotic leakage) and septic conditions of any cause in patients who undergo elective operations for colorectal cancer compared with a nutritional preparation that is identical apart from the EPA content.
Several earlier studies indicate that perioperative supplements of Omega-3 fatty acids can
reduce the risk of postoperative complications after major surgery through an immune
modulating effect in the form of a downward adjustment of the inflammatory response. (1-7)
The interpretation of these studies is made more difficult by differences in their method of
administration (parentally/enterally), differences in the time of the intervention
(preoperative/postoperative) and differences in the selection of patients (malnourished
cancer patients / upper GI cancer patients/mixed surgical patients) and finally because many
of the studies deal with a so-called immune modulating preparation containing a mixture of
arginine, Omega-3 fatty acids and ribonucleic acid.
The biological effects of fish oils are related to their content of such things as Omega-3
fatty acids that can be incorporated in cell membranes where they influence receptor
function, enzyme activity and the production of lipid mediators. The cells from the immune
system perform their functions through membrane-associated activities like secretion of
cytokines, antibodies, lymphocyte transformation and contact lysine. These functions can be
affected by changes in the membrane structure. (7;8) Besides the effect parameter of
postoperative septic complications, many of these studies use pseudoparameters such as
length of stay, need for respirator treatment, time in intensive care as well as a wide
range of biochemical changes whose relevance to the clinic process can be difficult to
assess. (1-7;9-13;). It is well-known that early enteral nutrition reduces the risk of
postoperative complications (14; 15). Many of the aforementioned studies similarly point to
a benefit from using Omega-3 fatty acid enriched nutritional preparations preoperatively.
There is now a commercially manufactured nutritional preparation for peroral consumption
containing Omega-3 fatty acids - Supportan (Fresenius-Kabi). The preparation is more energy
intensive than similar drink preparations, but does not otherwise differ in composition from
standard preparations. It is approved by the Danish Veterinary and Food Administration for
this study.
In 2 x 200ml of Supportan 3 g EPA and DHA are given daily. In other studies up to 10 g have
been given daily without side effects. (6; 16)
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |